Third Quarter 2025 LUPKYNIS Sales Grew 27% LUPKYNIS Sales Guidance for 2025 Raised to $265 Million to $270 Million Aritinercept Advances Toward Clinical Studies in Two Autoimmune Diseases ROCKVILLE, Md. & EDMONTON, Alberta / Nov 04, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Nov 03, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025. Aurinia’s management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the webcast is... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Oct 15, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS ® (voclosporin) at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24–29, and the American Society of Nephrology (ASN) Kidney Week... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Sep 29, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today responded to a now retracted LinkedIn post referencing voclosporin by an FDA official. Aurinia stands behind the favorable benefit/risk profile of LUPKYNIS ® (voclosporin). LUPKYNIS received full approval from the FDA in January 2021 based on a large, randomized 52-week clinical study known as AURORA 1.... Read More

ROCKVILLE, Md.& EDMONTON, Alberta / Jul 31, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2025. Financial Results Total Revenue: For the three and six months ended June 30, 2025, total revenue was $70.0 million and $132.5 million, up 22% and 23%, respectively, from $57.2 million and $107.5 million, respectively, for the same... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Jul 22, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release second quarter 2025 financial and operational results before markets open on July 31, 2025. Aurinia’s management team will host a conference call and webcast on July 31, 2025, at 8:30 a.m. ET. The link to the webcast is available here . To join the... Read More

Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Dosing Plan to Initiate Clinical Studies in at Least Two Autoimmune Diseases in the Second Half of This Year Aurinia to Host Conference Call Today, June 30, at 8:30 a.m. ET ROCKVILLE, Md. & EDMONTON, Alberta / Jun 30, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Jun 29, 2025 / Business Wire / Aurinia Pharmaceuticals Inc . (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here . To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access... Read More

LUPKYNIS Data Presented at LUPUS 2025, the 16 th International Congress on SLE, May 21-24 ROCKVILLE, Md. & EDMONTON, Alberta / May 22, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who received triple immunosuppressive therapy with LUPKYNIS ® (voclosporin),... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / May 12, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Total Revenue: For the three months ended March 31, 2025, total revenue was $62.5 million, up 24% from $50.3 million in the same period of 2024. Net Product Sales: For the three months ended March 31,... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / May 05, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025. Aurinia’s management team will host a conference call and webcast at 8:30 AM ET that day to review these results and provide a general business update. The link to... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Apr 30, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) today announced that leading independent proxy advisor Glass, Lewis & Co. LLC (“Glass Lewis”) has recommended that Aurinia shareholders vote FOR all proposals put forth by the Board of Directors (the “Board”) at the Company’s 2025 Annual General Meeting (the “Meeting”) on Thursday, May... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Apr 29, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) today announced that leading independent proxy advisor Institutional Shareholder Services (“ISS”) has recommended that Aurinia shareholders vote FOR all proposals put forth by the Board of Directors (the “Board”) at the Company’s 2025 Annual General Meeting (the “Meeting”) on Thursday,... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Feb 27, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress. Fourth Quarter 2024 Financial Results Total Revenue: For the three months ended December 31, 2024, total revenue was $59.9 million, up 33% from $45.1 million in the same... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Feb 20, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27, 2025. Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business... Read More

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen ROCKVILLE, Md. & EDMONTON, Alberta / Nov 18, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment,... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Nov 15, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manifestation of... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Nov 14, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Nov 07, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing companies in the biotechnology industry. He previously... Read More

Achieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively Generated $17.0 million in cash flow from operations in the third quarter and had cash, cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 Anticipates a one-time restructuring charge in the fourth quarter... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Oct 30, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024. Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Sep 24, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN). The Company’s collaboration partner, Otsuka Pharmaceutical Co., Ltd.,... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Sep 13, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the 2024 Cantor Fitzgerald Global Healthcare Conference in New York City, September 17-19, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday,... Read More

Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director Kevin Tang, President of Tang Capital Management, LLC, appointed as a Director The Board has accepted the conditional resignations of three directors who received less than majority support at the 2024 Annual General Meeting ROCKVILLE, Md. & EDMONTON, Alberta / Sep 12, 2024 / Business Wire / Aurinia Pharmaceuticals Inc . (NASDAQ: AUPH)... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Sep 05, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Aug 28, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in New York City, September 9-11, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on... Read More

Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter and had cash, cash equivalents, restricted cash and investments of $330.7 million as of June 30, 2024 Company announces development strategy... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Jul 19, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Jul 02, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, July 9-10, 2024, in Boston, and at the 3rd Annual H.C. Wainwright Virtual Kidney Conference, July 15, 2024. About Aurinia... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Jun 14, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Jun 05, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS ® (voclosporin), a... Read More

Raises Concerns Surrounding Lucien Selce's Self-Serving Proposals and Lack of Credibility Glass Lewis Recommends that Aurinia Shareholders Vote FOR the Re-Election to the Board of Directors of All Nine Incumbent Directors ROCKVILLE, Md. & EDMONTON, Alberta / Jun 04, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued the following letter to shareholders in response to a... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Jun 03, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) filed a supplement (the “Supplement”) to the Company’s Management Information and Proxy Statement dated June 3, 2024 (the “Proxy Statement/Circular”) for its Annual General Meeting of Shareholders to be held on June 14, 2024 (the “Annual Meeting”). The purpose of the Supplement is to reduce... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / May 30, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Jefferies Global Healthcare Conference in New York from June 4-6, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a presentation on Wednesday, June 5, from 8:00 to 8:25 AM Eastern Time. A live webcast... Read More

An updated analysis showed that LUPKYNIS is a cost-effective treatment for lupus nephritis, on par with other interventions for diabetes, blood pressure, and hyperlipidemia in adult patients with active lupus nephritis (LN). Additional data on baseline demographics from the Enlight-LN registry and safety and efficacy data of LUPKYNIS will also be presented. ROCKVILLE, Md. & EDMONTON, Alberta / May 14, 2024 / Business Wire /... Read More

A propensity analysis of ALMS, AURA-LV, and AURORA 1 suggested that initial therapy with LUPKYNIS plus standard of care reduced exposure to potential toxicities and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both mycophenolate mofetil and glucocorticoids alone. A post-hoc analysis showed Black patients experienced improved outcomes and better renal... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / May 07, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat on Wednesday, May 15, from 10:00 to 10:25 AM Eastern Time.... Read More

Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent growth in LUPKYNIS ® (voclosporin) sales Rapidly completed restructuring while maintaining focus on commercial execution Ahead of prior projections, Company expects to be cash flow positive,... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / May 01, 2024 / Business Wire / In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.... Read More

New data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year of treatment Safety profile remains unchanged and is aligned with the safety findings in the AURORA clinical program ROCKVILLE, Md. & EDMONTON, Alberta / Apr 30, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Apr 16, 2024 / Business Wire / NOTE: The new presentation time for Aurinia’s presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conferences is 4:00 to 4:30 PM Eastern Time. This event is presentation only. Webcast Details remain the same. The updated release reads: Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Apr 15, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Apr 09, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Feb 29, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Canadian securities regulators have granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the Current... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Feb 27, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that management will be participating in the following upcoming investor conferences during the month of March: TD Cowen’s 44th Annual Health Care Conference taking place March 4 - 6, 2024, at the Marriott Copley Place in Boston, MA. Aurinia management will host one-on-one... Read More

Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of cash, cash equivalents, restricted cash and investments as of December 31, 2023 Reaffirms 2024 net product revenue guidance of $200 - $220 million Announces conclusion of strategic review and details operational changes that are... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Feb 05, 2024 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2023 fourth quarter and full year financial and operational results on Thursday, February 15, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general... Read More

Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and full year 2023 of approximately $42 million and $159 million Approximately $351 million of cash, cash equivalents, restricted cash and investments as of December 31, 2023 (unaudited) Net product revenue guidance for 2024 in the... Read More

AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Upon FDA clearance of the IND, AUR 200 will be studied in a Phase 1 first-in-human trial in healthy volunteers, marking a significant advancement for Aurinia’s emerging autoimmune pipeline ROCKVILLE, Md. & EDMONTON, Alberta / Dec 20,... Read More

ROCKVILLE, Md. & EDMONTON, Alberta / Nov 13, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin,... Read More

A propensity analysis of AURORA 1 suggested that initial therapy with LUPKYNIS ® plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both mycophenolate mofetil and glucocorticoids alone. Patients treated with LUPKYNIS ® in a repeat kidney biopsy sub-study achieved improvement in histologic activity with stable... Read More

Patients treated with LUPKYNIS Ⓡ in a repeat kidney biopsy sub-study achieved improvement in histologic activity with stable chronicity scores and no evidence of chronic injury. A propensity analysis of AURORA 1 suggested that LUPKYNIS Ⓡ plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both glucocorticoids and... Read More

Net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter Total net revenue of $130.4 million for the nine months ended September 30, 2023, an increase of 24% over prior year Achieved European pricing and reimbursement milestone triggering $10 million payment from Otsuka Pharmaceutical Co. Ltd. Narrowing 2023 net product revenue guidance range to $155 - $160... Read More

Recommendations Published online in Annals of the Rheumatic Diseases Propose That Physicians Consider Earlier Intervention with Therapies Including LUPKYNIS ® (voclosporin) as a New LN Treatment Paradigm ROCKVILLE, Md. & EDMONTON, Alberta / Oct 26, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia welcomes the 2023 updated recommendations from The European Alliance of... Read More

EDMONTON, Alberta / Oct 19, 2023 / Business Wire / Note revised call-in number for participants 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada) The updated release reads: Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open. Aurinia’s management team... Read More

EDMONTON, Alberta / Oct 19, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2023, on Thursday, November 2, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.... Read More

EDMONTON, Alberta / Oct 13, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from 14 studies of LUPKYNIS ® (voclosporin) will be presented at the American Society of Nephrology (ASN) Kidney Week 2023, taking place November 2-5 in... Read More

EDMONTON, Alberta / Sep 21, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, “MKT Capital”) submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board. In connection with Dr. Foster’s... Read More

Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia’s Board of Directors August 18, 2023 Dr. Daniel G. Billen appointed Chair of the Board of Directors EDMONTON, Alberta / Aug 21, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined the board of directors of the... Read More

Net revenue increased to $41.5 million for second quarter of 2023; 47% over the prior year second quarter Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ® (voclosporin) Conference call to be hosted today at 8:30 a.m. ET EDMONTON, Alberta / Aug 03, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for... Read More

EDMONTON, Alberta / Jul 20, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.... Read More

EDMONTON, Alberta / Jul 19, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology , the official peer-reviewed journal of the American College of Rheumatology. As part of the AURORA Clinical Program, the AURORA 2 extension study... Read More

In Addition, Board has Accepted Recent Director Resignations and has Initiated a Search for New Directors EDMONTON, Alberta / Jun 29, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has initiated an exploration of strategic alternatives. As part of this process, the Board will consider a wide range of options for the company... Read More

LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with mycophenolate mofetil and low-dose steroids alone, in a pooled, post-hoc analysis. 1 LUPKYNIS® was associated with a higher rate of renal secretion and lower overall exposure to kidney tissue, which may be associated with an improved... Read More

EDMONTON, Alberta / Jun 01, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1 (NCT03021499) studies, which found that LUPKYNIS® with mycophenolate mofetil (MMF) and low-dose steroids resulted in earlier and greater reductions in proteinuria in lupus nephritis (LN)... Read More

EDMONTON, Alberta / May 26, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission (SEC). Under U.S. federal securities laws, equity awards issued as employee compensation must be registered under the Securities Act of 1933, as amended, via an S-8 registration... Read More

EDMONTON, Alberta / May 17, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced voting results for its annual general meeting (the “Meeting”) of shareholders held on May 17, 2023. Shareholders re-elected six of eight incumbent directors to the Board of Directors (the “Board”). Two directors, George Milne and Joseph (“Jay”) Hagan, while elected under applicable... Read More

First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS ® (voclosporin) Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms from baseline to follow-up Activity scores decreased in conjunction with improvements in urine protein creatinine ratio (UPCR) in both treatment arms Data further reinforces... Read More

$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS Significant progress across Commercial, R&D and Intellectual Property Conference call to be hosted today at 8:30 a.m. ET EDMONTON, Alberta / May 04, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ:... Read More

EDMONTON, Alberta / May 03, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including mixed class III/V and IV/V) 1 , when provided in combination with mycophenolate mofetil... Read More

Both leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia’s continued momentum Company to release first quarter financial and operational results on May 4, 2023 Shareholders with questions or who require... Read More

EDMONTON, Alberta / May 02, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS ® (voclosporin) in combination with a background immunosuppressive therapy to treat adults with active class III, IV and V (including mixed classes III/V and IV/V) lupus nephritis... Read More

Leading independent proxy advisor also recommends shareholders vote for say-on-pay, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia’s continued momentum Shareholders with questions or who require assistance voting their shares should contact Laurel Hill Advisory Group toll free within North America at... Read More

Braxton, a seven-time Grammy Award-winning singer, songwriter, actress, producer, and entrepreneur, will share her personal lupus journey to empower people with lupus and lupus nephritis to prioritize their kidney health as part of Aurinia’s Get Uncomfortable campaign The Get Uncomfortable campaign is designed to educate and motivate people living with lupus nephritis to protect their kidneys by going to the doctor and... Read More

EDMONTON, Alberta / Apr 24, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2023, on Thursday, May 4, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested... Read More

New method of use patent (U.S. Patent No. 11,622,991) issued for LUPKYNIS Reflects the unique and proprietary dosing regimen indicated for LUPKINIS in Lupus Nephritis Announcement is a follow-up to previously announced allowance from the USPTO on application (No. 17,713/140); now issued U.S. patent (No. 11,622,991) EDMONTON, Alberta / Apr 11, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the... Read More

LUPKYNIS ® treated patients showed histologic activity improvement with stable chronicity scores similar to active control arm of mycophenolate mofetil (MMF) and low dose steroids alone Data further reinforces differentiation of LUPKYNIS from first generation calcineurin inhibitors (CNIs) Conference call to be hosted today at 8:30 a.m. EDT EDMONTON, Alberta / Apr 05, 2023 / Business Wire / Aurinia Pharmaceuticals Inc.... Read More

EDMONTON, Alberta / Apr 03, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune, kidney and rare diseases, announced that the Company’s Compensation Committee granted 4 new employees inducement stock options to purchase an aggregate of 111,620 common shares, at a per share exercise... Read More

VICTORIA, British Columbia / Mar 06, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune, kidney and rare diseases, announced that the Company’s Compensation Committee granted 3 new employees inducement stock options to purchase an aggregate of 89,830 common shares, at a per share... Read More

VICTORIA, British Columbia / Feb 28, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the fourth quarter and the full year ended December 31, 2022. Amounts are expressed in U.S. dollars. Aurinia achieved total net revenue of $28.4 million and $134.0 million for the fourth quarter and full year ended December 31, 2022, respectively. Aurinia... Read More

VICTORIA, British Columbia / Feb 24, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference. Oppenheimer 33rd Annual Virtual Healthcare Conference being held March 13 – 15, 2023. Presentation time Tuesday, March 14, from 9:20 – 9:50... Read More

VICTORIA, British Columbia / Feb 07, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday, February 28, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general... Read More

VICTORIA, British Columbia / Feb 06, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s Compensation Committee granted 7 new employees inducement stock options to purchase an aggregate of 70,070 common shares, at a per share exercise price of... Read More

VICTORIA, British Columbia / Jan 25, 2023 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036. About LUPKYNIS LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes... Read More

Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million Preliminary unaudited net product revenue for the fourth quarter and full year 2022 of approximately $28.3 million and $103.5 million Reiterates net product revenue guidance for 2023 in the range of $120-$140 million Approximately $388.7 million of cash, cash equivalents, restricted cash and... Read More

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11 th at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time in San Francisco, CA. To participate in the audio webcast, interested parties can access the live webcast under "News/Events”... Read More

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s Compensation Committee granted 2 new employees inducement stock options to purchase an aggregate of 12,650 common shares, at a per share exercise price of $5.94, the closing price of Aurinia's common stock on January 3,... Read More

Sun Pharmaceuticals and Aurinia agreed to file a joint motion to dismiss Inter Parties Review of Patent No. 10,286,036 Parties have settled the patent infringement claim against Sun’s CEQUA® product Settlements are Contingent Upon U.S. Patent Trial and Appeal Board (PTAB) Terminating Inter Partes Review Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement... Read More